Skip to main content

Table 1 Patients’ characteristics with metastatic gastric cancer

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

  BCc1 nanomedicine
(n = 33)
Placebo
(n = 30)
Age, years
 Mean (SD) 59.8 ± 13 61.2 ± 12.93
Weight
 Mean (SD) 61.68 ± 12.24 55.62 ± 12.82
Gender (n)
 Male–female 23–10 20–10
Metastatic site (n)
 Liver 17 11
 Multiple site 9 10
 Lung 2 3
 Peritoneal carcinomatosis 5 4
Stage 4 (n) 33 30
 Site of involvement (n)
  Cardia 7 10
  Antrum 6 5
  Fundus 3 3
  Greater curvature 3 4
  Lesser curvature 4 3
  Diffuse 4 5
Intervention + chemotherapy (n) 14 19
Intervention + chemotherapy + radiotherapy (n) 0 1